XH001 with neoantigen vaccine–primed tumor-specific T cells for advanced gastrointestinal cancer

A Single-center, Non-randomized, Open-label Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer

This trial tests whether combining XH001 injections with T cells activated by a tumor neoantigen vaccine is safe and can shrink tumors or extend life in adults with advanced gastrointestinal cancer.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Ages: 18 Years to 70 Years
• Sex: All
• Sponsor: Beijing GoBroad Hospital (Academic / other)
• Drugs / interventions: chemotherapy, immunotherapy, prednisone
• Locations: 1 site (Beijing)
• Trial ID: NCT07329894 on ClinicalTrials.gov

What this trial studies

This Phase 1, interventional study combines an investigational agent (XH001) with tumor neoantigen vaccine–induced, tumor-specific T-cell infusions in adults who have advanced gastrointestinal cancer and have failed or cannot tolerate standard second-line treatments. The primary focus is on safety and tolerability, with careful monitoring for adverse events and immune-related reactions. Secondary and exploratory measures include tumor response by RECIST 1.1, changes in tumor burden, and preliminary signals of survival benefit. Treatment and follow-up are conducted at a single site, with eligibility requiring measurable disease and adequate organ function.

Who should consider this trial

Good fit: Adults aged 18–70 with histologically confirmed advanced gastrointestinal cancer, a measurable lesion per RECIST 1.1, expected survival of at least 12 weeks, and adequate organ and bone marrow function who have failed or are intolerant of standard second-line therapy are the intended participants.

Not a fit: Patients with poor organ or bone marrow function, life expectancy under 12 weeks, no measurable disease per the trial criteria, or those doing well on standard treatments are unlikely to benefit from this early-phase experimental approach.

Why it matters

Potential benefit: If successful, the combination could produce targeted immune attacks that shrink tumors and potentially prolong survival for some patients with advanced gastrointestinal cancer.

How similar studies have performed: Early-phase research combining neoantigen vaccines and adoptive T-cell approaches has produced promising immune responses in some cancers but definitive clinical benefit remains limited and this specific combination is relatively novel.

Eligibility criteria

Inclusion Criteria:

* Provision of signed and dated informed consent form.
* Aged between 18 and 70 years old, male or female.
* Advanced gastrointestinal cancer that has been diagnosed by histological and/or cellular pathology, and which has failed to respond to second-line standard treatment or is intolerant to it, or is not suitable for standard treatment at this stage.
* According to the RECIST 1.1 criteria for evaluating the efficacy of solid tumors, there must be at least one measurable lesion as the target lesion for efficacy evaluation. The total diameter of the overall tumor lesion (excluding bone metastases) should be ≤ 100mm, and the diameter of a single tumor lesion should be ≤ 30mm. If the lesion that has received local treatment (radiotherapy, ablation, vascular intervention, etc.) is the only lesion, then there must be clear imaging evidence of disease progression for this lesion.
* Expected survival duration ≥ 12 weeks.
* Adequate organ and bone marrow function.

Exclusion Criteria:

* Requires long-term systemic administration of antiallergic drugs, or has severe hypersensitivity reactions (≥Grade 3) to XH001 injection and/or any of its excipients.
* Central nervous system metastases with symptoms, and/or meningeal metastases.
* Having received immunomodulatory drug therapy within 2 weeks prior to the first administration day (D1) of XH001 injection.
* Suffer from skin diseases that may prevent the intradermal injection from reaching the target area (such as psoriasis).
* Subjects with toxic side effects from previous treatment that have not recovered to CTCAE grade≤2, excluding hair loss.
* Subjects who received systemic steroid treatment (daily dose exceeding 10mg of prednisone equivalent) or any other form of immunosuppressive treatment within 7 days before the first administration of XH001 injection, excluding:1) Intranasal inhalation of local steroids or local steroid injection (such as intra-articular injection); 2) Systemic corticosteroid treatment not exceeding 10mg/day of prednisone or its equivalent physiological dose.
* Subjects who have previously received therapeutic tumor vaccines or therapeutic cell therapy products.
* Previously received allogeneic hematopoietic stem cell or allogeneic bone marrow transplantation, or previously received solid organ transplantation, or currently using immunosuppressive drugs.
* Have active or poorly controlled severe infections during screening period.
* Virological tests show positive for human immunodeficiency virus antibodies, hepatitis B surface antigen and/or hepatitis B core antibody with hepatitis B virus DNA \> 1000 IU/ml, positive for hepatitis C virus antibodies, and positive for Treponema pallidum specific antibodies.
* Patients with other malignancies within 5 years before enrollment, except for those with a history of appropriately treated and cured cervical carcinoma in situ, breast carcinoma in situ, or skin basal cell carcinoma.
* Any history of autoimmune diseases.
* Known to have active pulmonary tuberculosis (TB).
* Patients who have received systemic chemotherapy, radiotherapy, molecular targeted therapy, biological immunotherapy, hormone therapy or unapproved clinical trial drugs/instruments within 2 weeks before screening.
* Subjects who are still participating in other clinical trials during the screening period.
* Pregnant or lactating women.
* Other severe, acute, or chronic medical or psychiatric conditions, or laboratory abnormalities, that, to the investigator's discretion, may increase the risks of participating in the trial or may interfere with the interpretation of the trial results.

Where this trial is running

Beijing

• Beijing Gobroad Hospital — Beijing, China (Recruiting)

Study contacts

• Study coordinator: Changsong Qi, MD

Conditions Gastrointestinal Cancer; Tumor Neoantigen Vaccine; Adoptive Cell Therapy